

# Minutes Drug Utilization Review Board Meeting

**DATE:** 9/13/13



**Meeting Purpose:** Quarterly Open Board Meeting  
Meeting opened at 6:00 P.M. by Chair, Adam Burrows

## Agenda Items:

- I. Welcome and Introductory Remarks
- II. Hepatitis Antiviral Agents QA
- III. Acne Agents QA
- IV. Deferiprone (Ferroprox) QA
- V. MassHealth Drug List Update
- VI. DUR Operational Update
- VII. MassHealth Update

Agenda Item	Discussion	Conclusions/Follow Up
<b>Review of Minutes</b>	The June 12, 2013 Minutes were reviewed and accepted as written.	<b>Follow Up:</b> N/A
<b>Action</b>	June Minutes approved as noted.	<b>Conclusion:</b> N/A

Agenda Item	Discussion	Conclusions/Follow Up
<b>Hepatitis Antiviral Agents QA</b>	A quality assurance analysis (QA) for the hepatitis C protease inhibitors was discussed.	<b>Follow Up:</b> Informational
<b>Action</b>	Discussed the following: <ul style="list-style-type: none"> <li>• Background pertaining to the hepatitis C protease inhibitors</li> <li>• Current PA requirements for all agents in this class and the approval criteria</li> <li>• Utilization trends and PA data for most recent six months</li> <li>• Historical trend illustrates a slow decrease in utilization</li> <li>• QA analysis demonstrates that prescribers are using the hepatitis C protease inhibitors appropriately</li> <li>• Issue of greatest concern is the identified waste that occurs when a member is approved to start therapy, the pharmacy dispensed the medication, and member does not commence therapy.</li> </ul>	<b>Conclusion:</b> Proceed with proposed changes as stated.

	No changes to the current prior authorization approval criteria are recommended at this time.	
--	---	--

Agenda Item	Discussion	Conclusions/Follow Up
<b>Acne Agents QA</b>	A quality assurance analysis (QA) for the Acne Agents was discussed.	<b>Follow Up:</b> Informational
<b>Action</b>	<p>Discussed the following:</p> <ul style="list-style-type: none"> <li>• Background pertaining to the acne agents</li> <li>• Current PA requirements for all agents in this class and the approval criteria</li> <li>• Utilization trends and PA data for most recent six months</li> </ul> <p>Proposed the following:</p> <ul style="list-style-type: none"> <li>• Clarify approval criteria for Aczone, Azelex<sup>®</sup> and Finacea</li> <li>• Require PA for metronidazole 1%</li> </ul>	<b>Conclusion:</b> Proceed with proposed changes as stated.

Agenda Item	Discussion	Conclusions/Follow Up
<b>Deferiprone (Ferriprox) QA</b>	A quality assurance analysis (QA) for the deferiprone (Ferriprox) was discussed.	<b>Follow Up:</b> Informational
<b>Action</b>	<p>Discussed the following:</p> <ul style="list-style-type: none"> <li>• Background pertaining to deferiprone (Ferriprox) and thalassemias and the need for iron chelation therapy</li> <li>• Current PA requirements for deferiprone (Ferriprox) and other agents used for iron chelation and approval criteria</li> <li>• Utilization trends and PA data</li> <li>• Clinical studies currently in development to evaluate other uses of deferiprone (Ferriprox)</li> <li>• Recent expanded indication for deferasirox (Exjade)</li> </ul> <p>No changes to the current prior authorization approval criteria are recommended at this time.</p>	<b>Conclusion:</b> Proceed with proposed changes as stated.

Agenda Item	Discussion	Conclusions/Follow Up
<b>MassHealth Drug List Update</b>	Overview of the Drug List additions effective September 30, 2013, and the Drug List changes effective October 14, 2013.	<b>Follow Up:</b> N/A

<b>Action</b>	<p>There are nine new additions effective September 30, 2013. Changes in Prior Authorization status effective October 14, 2013, were also reviewed.</p> <p>Other updates included: One new PA forms and updates to two therapeutic tables.</p>	<p><b>Conclusion:</b> Changes in the MassHealth Drug List will continue to be provided as needed.</p>
---------------	--	---

Agenda Item	Discussion	Conclusions/Follow Up
<b>DUR Operational Update</b>	Quarterly Operations Update	<b>Follow Up:</b> Informational
<b>Action</b>	<p>DUR Operations monthly workload includes the following:</p> <ul style="list-style-type: none"> <li>• Average of 6,000 PA requests</li> <li>• Average of over 7,000 calls <ul style="list-style-type: none"> <li>○ Average abandonment rate a little over 1.0 %</li> <li>○ Average treatment time of under 4 minutes</li> </ul> </li> <li>• Average of 10 appeals</li> <li>• Average of 400 Provider outreach calls</li> <li>• Top 10 medications for which PA was requested: Suboxone, atorvastatin, Lidoderm, Cymbalta, Lyrica, Abilify, OxyContin, Advair, Strattera, montelukast</li> </ul>	<p><b>Conclusion:</b> Quarterly operational updates will continue to be provided as needed.</p>

Agenda Item	Discussion	Conclusions/Follow Up
<b>MassHealth Update</b>	Quarterly MassHealth Update	<b>Follow Up</b> Informational
<b>Action</b>	<p>Provided MassHealth Quarterly Update</p> <ul style="list-style-type: none"> <li>• Pharmacy processing was converted to POPS3 on 8/25/13</li> <li>• MassHealth will be convening workgroups for opioids, substance abuse, and behavioral health psychotropic use in foster children.</li> <li>• As part of the Affordable Care Act the state is implementing <ul style="list-style-type: none"> <li>○ Medicaid expansion in 1/1/14</li> <li>○ Creating a health insurance exchange in-line with federal requirements</li> <li>○ Integrating dually eligible members with integrated care organizations (ICOs)</li> </ul> </li> </ul>	<p><b>Conclusions:</b> N/A</p>

Respectfully submitted by: Vincent Palumbo, Director of DUR

Date: \_\_\_\_\_